BioMed Research International

Basic and Translational Advances in Glioblastoma


Status
Published

1UT Southwestern Medical Center, Dallas, USA

2University Hospital of Navarra, Pamplona, Spain

3Pisa University Hospital, Pisa, Italy


Basic and Translational Advances in Glioblastoma

Description

Glioblastoma is diagnosed using histopathological features and includes multiple variants. In the last years, the advent of next generation sequencing technologies has allowed the interrogation of the genetic landscape of glioblastoma at high resolution. As a result, cellular and molecular heterogeneity have been described among patients. This represents a milestone in glioblastoma research, although clinical applications for the benefit of patients are yet to come.

Due to the high degree of heterogeneity, little is known about the molecular events underpinning the genesis of glioblastoma and the disease is already advanced at clinical presentation, thus complicating the efficacy of therapies.

This special issue is intended to focus on novel basic and translational advances in glioblastoma research which are expected to impact on patient treatment and improve survival.

Potential topics include but are not limited to the following:

  • Novel therapeutic approaches targeting tumour-initiating cells
  • The impact of intratumour heterogeneity on therapy resistance
  • Molecular mechanisms of tumour growth and invasion
  • Evolutionary dynamics after therapy
  • Advances in tumour sampling and circulating tumour cells and cell-free DNA
  • Novel in vitro and in vivo models for drug screening
  • Improving the molecular-based and imaging-based proposed classifications of glioblastoma
  • Cell of origin and tumour-initiating cells
BioMed Research International
 Journal metrics
See full report
Acceptance rate24%
Submission to final decision83 days
Acceptance to publication22 days
CiteScore5.000
Journal Citation Indicator0.600
Impact Factor3.246
 Submit

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.